Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

132

Participants

Timeline

Start Date

February 26, 2026

Primary Completion Date

April 26, 2030

Study Completion Date

April 26, 2030

Conditions

Acute Myeloid LeukemiaMyelodysplastic Syndrome

Interventions

PROCEDURE

Biospecimen Collection

Undergo collection of blood samples

PROCEDURE

Bone Marrow Aspiration

Undergo bone marrow aspiration

PROCEDURE

Bone Marrow Biopsy

Undergo bone marrow biopsy

DRUG

Decitabine and Cedazuridine

Given PO

DRUG

Olutasidenib

Given PO

DRUG

Venetoclax

Given PO

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH